Oral DLBS1033 as Adjunctive Therapy in Acute Ischemic Stroke: Impact on Inflammatory Biomarkers and Outcomes

NCT07121569 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Ischemic Stroke, Acute

Interventions

DRUG: Oral lumbrokinase DLBS1033
DRUG: Placebo

Sponsor

Universitas Sebelas Maret